A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multicenter Study to Evaluate the Efficacy and Safety of Tadalafil Once-Daily Dosing for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia and Erectile Dysfunction

Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multicenter Study to Evaluate the Efficacy and Safety of Tadalafil Once-Daily Dosing for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia and Erectile Dysfunction

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Jun 2017

At a glance

  • Drugs Tadalafil (Primary) ; Tamsulosin
  • Indications Benign prostatic hyperplasia; Erectile dysfunction
  • Focus Registrational; Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 27 Jan 2016 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
    • 15 Feb 2015 Planned End Date changed from 1 Mar 2016 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
    • 15 Feb 2015 Planned primary completion date changed from 1 Mar 2016 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top